Drug Type Biosimilar, Monoclonal antibody |
Synonyms Ustekinumab Biosimilar (Ivy Pharma, Inc.) |
Target |
Action inhibitors |
Mechanism IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Preclinical | United States | 01 Nov 2024 | |
Crohn Disease | Preclinical | United States | 01 Nov 2024 | |
Psoriasis | Preclinical | United States | 01 Nov 2024 |